Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our ...
Don't Miss our Black Friday Offers: Terence Flynn’s rating is based on the performance and potential of Eli Lilly & Co’s key products, particularly Mounjaro and Zepbound. These medications ...
Eli Lilly’s new products (products launched since 2022 like Ebglyss, Jaypirca, Mounjaro, Kisunla, Omvoh and Zepbound) contributed $4.51 billion to revenues, led by Mounjaro and Zepbound.
Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows The FDA approved tirzepatide as Mounjaro for adults with type 2 ...
Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows The FDA approved tirzepatide as Mounjaro for adults with type 2 diabetes to ...
While this adds competition to a market currently controlled by Eli Lilly and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy and Zepbound. Amgen reported on Tuesday that ...